FDA Approves LP.8.1 COVID-19 Vaccines
August 27, 2025
-
3 min
The US FDA has approved LP.8.1-targeted COVID-19 vaccines for adults aged 65 and older and higher-risk individuals for the 2025-2026 season. Pfizer-BioNTech's Comirnaty LP.8.1, Moderna's Spikevax and mNEXSPIKE, and Novavax's Nuvaxovid are among the authorized vaccines, with distribution starting soon in pharmacies and clinics. These approvals are based on comprehensive safety and efficacy data. Vaccines continue to be available for patients following discussions with their physicians, while additional risks, such as rare allergic reactions, have also been reported.
1. FDA approved COVID-19 vaccines for older adults and high-risk patients.2. Vaccines include Pfizer-BioNTech’s Comirnaty, Moderna’s Spikevax, and Novavax’s Nuvaxovid.3. Distribution of vaccines will start immediately in pharmacies and clinics.4. Common side effects include pain and fatigue, with rare severe allergies.5. Vaccines may not protect all, especially immunocompromised patients.
Listen Tab content
